Ganaplacide(KAF156)联合鲁美泛群固体分散体制剂治疗无并发症恶性疟疾:一项开放标签、多中心、平行组、随机对照2期试验
该开放标签、多中心、随机对照2期试验在非洲和亚洲10国的13个研究中心开展,评估Ganaplacide联合鲁美泛群固体分散体制剂治疗无并发症恶性疟疾的疗效与安全性。Part A在成人及青少年中确定最佳剂量方案,Part B在儿童中验证。结果显示所有方案第29天PCR校正的充分临床和寄生虫学应答率95%CI下限均>80%,3天方案被确定为成人和儿童的最佳方案,组合总体耐受良好。
要点
- Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg每日一次连用3天为成人和儿童的最佳方案。
- Part B中仅3天方案达到预设主要终点,PCR校正应答率95%(95%CI 83-99)。
- 研究中未出现死亡,常见不良事件为头痛和疟疾。
核心结论
- Ganaplacide联合鲁美泛群-SDF在无并发症恶性疟疾患者中有效且耐受良好,尤其在成人和青少年中。
- Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg每日一次连用3天被确定为成人、青少年和儿童的最佳治疗方案。
- 该联合方案正在一项2期试验(NCT04546633)中进一步评估。
研究设计与样本
- 开放标签、多中心、平行组、随机对照2期试验,在非洲和亚洲10国的13个研究诊所和综合医院开展。
- 入组患者为显微镜确诊的无并发症恶性疟疾,原虫密度>1000且<150 000个/μL。
- Part A在成人及青少年(≥12岁)中比较7种方案(含对照),按国家分层(2:2:2:2:2:2:1),随机区组大小13;Part B在儿童(≥2岁且<12岁)中比较4种方案(含对照),按国家和年龄分层(2:2:2:2:1),随机区组大小7。
- 主要疗效终点为第29天PCR校正的充分临床和寄生虫学应答率,在意向性治疗集(符合方案集)中分析;零假设为应答率≤80%,当双侧95%CI下限>80%时拒绝零假设。
- 2017年8月2日至2021年5月17日筛查1220例患者,其中12例纳入run-in队列,Part A 337例,Part B 175例。
主要发现
- Part A中所有治疗方案的PCR校正第29天应答率95%CI下限均>80%:Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg 1天组46/50(92%,95%CI 81-98),2天组47/48(98%,89-100),3天组42/43(98%,88-100);Ganaplacide 800 mg联合鲁美泛群-SDF 960 mg单次给药组45/48(94%,83-99);Ganaplacide 200 mg联合鲁美泛群-SDF 480 mg 3天组47/47(100%,93-100);Ganaplacide 400 mg联合鲁美泛群-SDF 480 mg 3天组44/44(100%,92-100);蒿甲醚联合鲁美泛群对照组25/25(100%,86-100)。
- Part B中仅3天方案达到预设主要终点:Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg每日一次连用3天组38/40(95%,95%CI 83-99) vs 蒿甲醚联合鲁美泛群对照组21/22(96%,77-100)。
- Part A最常见不良事件为头痛,Ganaplacide联合鲁美泛群-SDF组为7/51(14%)至15/54(28%),蒿甲醚联合鲁美泛群组为5/27(19%)。
- Part B最常见不良事件为疟疾,Ganaplacide联合鲁美泛群-SDF组为12/45(27%)至23/52(44%),蒿甲醚联合鲁美泛群组为12/24(50%)。
- 研究期间无患者死亡。
关键数值与推荐
- Part A中Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg每日一次连用3天方案第29天PCR校正应答率为98%(95%CI 88-100)。
- Part B中Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg每日一次连用3天方案第29天PCR校正应答率为95%(95%CI 83-99)。
- 最佳治疗方案为Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg每日一次连用3天,适用于成人、青少年和儿童。
临床怎么用
- 作者认为Ganaplacide联合鲁美泛群-SDF在无并发症恶性疟疾患者中有效且耐受良好,尤其成人和青少年。
- 作者确定Ganaplacide 400 mg联合鲁美泛群-SDF 960 mg每日一次连用3天为成人、青少年和儿童的最佳治疗方案。
- 该联合方案正在一项2期试验(NCT04546633)中进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emergence of drug resistance demands novel antimalarial drugs with new mechanisms of action. We aimed to identify effective and well tolerated doses of ganaplacide plus lumefantrine solid dispersion formulation (SDF) in patients with uncomplicated Plasmodium falciparum malaria. METHODS: This open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial was conducted at 13 research clinics and general hospitals in ten African and Asian countries. Patients had microscopically-confirmed uncomplicated P falciparum malaria (>1000 and <150 000 parasites per μL). Part A identified the optimal dose regimens in adults and adolescents (aged ≥12 years) and in part B, the selected doses were assessed in children (≥2 years and <12 years). In part A, patients were randomly assigned to one of seven groups (once a day ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 1, 2, or 3 days; ganaplacide 800 mg plus lumefantrine-SDF 960 mg as a single dose; once a day ganaplacide 200 mg plus lumefantrine-SDF 480 mg for 3 days; once a day ganaplacide 400 mg plus lumefantrine-SDF 480 mg for 3 days; or twice a day artemether plus lumefantrine for 3 days [control]), with stratification by country (2:2:2:2:2:2:1) using randomisation blocks of 13. In part B, patients were randomly assigned to one of four groups (once a day ganaplacide 400 mg plus lumefantrine-SDF 960 mg for 1, 2, or 3 days, or twice a day artemether plus lumefantrine for 3 days) with stratification by country and age (2 to <6 years and 6 to <12 years; 2:2:2:1) using randomisation blocks of seven. The primary efficacy endpoint was PCR-corrected adequate clinical and parasitological response at day 29, analysed in the per protocol set. The null hypothesis was that the response was 80% or lower, rejected when the lower limit of two-sided 95% CI was higher than 80%. This study is registered with EudraCT (2020-003284-25) and ClinicalTrials.gov (NCT03167242). FINDINGS: Between Aug 2, 2017, and May 17, 2021, 1220 patients were screened and of those, 12 were included in the run-in cohort, 337 in part A, and 175 in part B. In part A, 337 adult or adolescent patients were randomly assigned, 326 completed the study, and 305 were included in the per protocol set. The lower limit of the 95% CI for PCR-corrected adequate clinical and parasitological response on day 29 was more than 80% for all treatment regimens in part A (46 of 50 patients [92%, 95% CI 81-98] with 1 day, 47 of 48 [98%, 89-100] with 2 days, and 42 of 43 [98%, 88-100] with 3 days of ganaplacide 400 mg plus lumefantrine-SDF 960 mg; 45 of 48 [94%, 83-99] with ganaplacide 800 mg plus lumefantrine-SDF 960 mg for 1 day; 47 of 47 [100%, 93-100] with ganaplacide 200 mg plus lumefantrine-SDF 480 mg for 3 days; 44 of 44 [100%, 92-100] with ganaplacide 400 mg plus lumefantrine-SDF 480 mg for 3 days; and 25 of 25 [100%, 86-100] with artemether plus lumefantrine). In part B, 351 children were screened, 175 randomly assigned (ganaplacide 400 mg plus lumefantrine-SDF 960 mg once a day for 1, 2, or 3 days), and 171 completed the study. Only the 3-day regimen met the prespecified primary endpoint in paediatric patients (38 of 40 patients [95%, 95% CI 83-99] vs 21 of 22 [96%, 77-100] with artemether plus lumefantrine). The most common adverse events were headache (in seven [14%] of 51 to 15 [28%] of 54 in the ganaplacide plus lumefantrine-SDF groups and five [19%] of 27 in the artemether plus lumefantrine group) in part A, and malaria (in 12 [27%] of 45 to 23 [44%] of 52 in the ganaplacide plus lumefantrine-SDF groups and 12 [50%] of 24 in the artemether plus lumefantrine group) in part B. No patients died during the study. INTERPRETATION: Ganaplacide plus lumefantrine-SDF was effective and well tolerated in patients, especially adults and adolescents, with uncomplicated P falciparum malaria. Ganaplacide 400 mg plus lumefantrine-SDF 960 mg once daily for 3 days was identified as the optimal treatment regimen for adults, adolescents, and children. This combination is being evaluated further in a phase 2 trial (NCT04546633). FUNDING: Novartis and Medicines for Malaria Venture.
引用
- Ogutu B, Yeka A, Kusemererwa S, et al. Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial. Lancet Infect Dis. 2023. PMID: 37327809. doi:10.1016/S1473-3099(23)00209-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。